Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AHB-137 in HBeAg-negative Chronic Hepatitis B
NCT06550128Phase 2Completed
- Sponsor
- AusperBio
- Start
- Jul 2024
- Primary completion
- May 2025
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AHB-137 in Chronic Hepatitis B (CHB) (3 arms), sponsored by AusperBio. Primary endpoint: Proportion of participants achieving HBsAg < LOD and HBV DNA < LLOQ at 24 weeks. Started Jul 2024; status: completed.
02
Drugs
AHB-137
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06550128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06550128.